Cargando…

Dynamical Boolean Modeling of Immunogenic Cell Death

As opposed to the standard tolerogenic apoptosis, immunogenic cell death (ICD) constitutes a type of cellular demise that elicits an adaptive immune response. ICD has been characterized in malignant cells following cytotoxic interventions, such as chemotherapy or radiotherapy. Briefly, ICD of cancer...

Descripción completa

Detalles Bibliográficos
Autores principales: Checcoli, Andrea, Pol, Jonathan G., Naldi, Aurelien, Noel, Vincent, Barillot, Emmanuel, Kroemer, Guido, Thieffry, Denis, Calzone, Laurence, Stoll, Gautier
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7690454/
https://www.ncbi.nlm.nih.gov/pubmed/33281620
http://dx.doi.org/10.3389/fphys.2020.590479
_version_ 1783614071749214208
author Checcoli, Andrea
Pol, Jonathan G.
Naldi, Aurelien
Noel, Vincent
Barillot, Emmanuel
Kroemer, Guido
Thieffry, Denis
Calzone, Laurence
Stoll, Gautier
author_facet Checcoli, Andrea
Pol, Jonathan G.
Naldi, Aurelien
Noel, Vincent
Barillot, Emmanuel
Kroemer, Guido
Thieffry, Denis
Calzone, Laurence
Stoll, Gautier
author_sort Checcoli, Andrea
collection PubMed
description As opposed to the standard tolerogenic apoptosis, immunogenic cell death (ICD) constitutes a type of cellular demise that elicits an adaptive immune response. ICD has been characterized in malignant cells following cytotoxic interventions, such as chemotherapy or radiotherapy. Briefly, ICD of cancer cells releases some stress/danger signals that attract and activate dendritic cells (DCs). The latter can then engulf and cross-present tumor antigens to T lymphocytes, thus priming a cancer-specific immunity. This series of reactions works as a positive feedback loop where the antitumor immunity further improves the therapeutic efficacy by targeting cancer cells spared by the cytotoxic agent. However, not all chemotherapeutic drugs currently approved for cancer treatment are able to stimulate bona fide ICD: some commonly used agents, such as cisplatin or 5-fluorouracil, are unable to activate all features of ICD. Therefore, a better characterization of the process could help identify some gene or protein candidates to target pharmacologically and suggest combinations of drugs that would favor/increase antitumor immune response. To this end, we have built a mathematical model of the major cell types that intervene in ICD, namely cancer cells, DCs, CD8(+) and CD4(+) T cells. Our model not only integrates intracellular mechanisms within each individual cell entity, but also incorporates intercellular communications between them. The resulting cell population model recapitulates key features of the dynamics of ICD after an initial treatment, in particular the time-dependent size of the different cell types. The model is based on a discrete Boolean formalism and is simulated by means of a software tool, UPMaBoSS, which performs stochastic simulations with continuous time, considering the dynamics of the system at the cell population level with appropriate timing of events, and accounting for death and division of each cell type. With this model, the time scales of some of the processes involved in ICD, which are challenging to measure experimentally, have been predicted. In addition, our model analysis led to the identification of actionable targets for boosting ICD-induced antitumor response. All computational analyses and results are compiled in interactive notebooks which cover the presentation of the network structure, model simulations, and parameter sensitivity analyses.
format Online
Article
Text
id pubmed-7690454
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-76904542020-12-04 Dynamical Boolean Modeling of Immunogenic Cell Death Checcoli, Andrea Pol, Jonathan G. Naldi, Aurelien Noel, Vincent Barillot, Emmanuel Kroemer, Guido Thieffry, Denis Calzone, Laurence Stoll, Gautier Front Physiol Physiology As opposed to the standard tolerogenic apoptosis, immunogenic cell death (ICD) constitutes a type of cellular demise that elicits an adaptive immune response. ICD has been characterized in malignant cells following cytotoxic interventions, such as chemotherapy or radiotherapy. Briefly, ICD of cancer cells releases some stress/danger signals that attract and activate dendritic cells (DCs). The latter can then engulf and cross-present tumor antigens to T lymphocytes, thus priming a cancer-specific immunity. This series of reactions works as a positive feedback loop where the antitumor immunity further improves the therapeutic efficacy by targeting cancer cells spared by the cytotoxic agent. However, not all chemotherapeutic drugs currently approved for cancer treatment are able to stimulate bona fide ICD: some commonly used agents, such as cisplatin or 5-fluorouracil, are unable to activate all features of ICD. Therefore, a better characterization of the process could help identify some gene or protein candidates to target pharmacologically and suggest combinations of drugs that would favor/increase antitumor immune response. To this end, we have built a mathematical model of the major cell types that intervene in ICD, namely cancer cells, DCs, CD8(+) and CD4(+) T cells. Our model not only integrates intracellular mechanisms within each individual cell entity, but also incorporates intercellular communications between them. The resulting cell population model recapitulates key features of the dynamics of ICD after an initial treatment, in particular the time-dependent size of the different cell types. The model is based on a discrete Boolean formalism and is simulated by means of a software tool, UPMaBoSS, which performs stochastic simulations with continuous time, considering the dynamics of the system at the cell population level with appropriate timing of events, and accounting for death and division of each cell type. With this model, the time scales of some of the processes involved in ICD, which are challenging to measure experimentally, have been predicted. In addition, our model analysis led to the identification of actionable targets for boosting ICD-induced antitumor response. All computational analyses and results are compiled in interactive notebooks which cover the presentation of the network structure, model simulations, and parameter sensitivity analyses. Frontiers Media S.A. 2020-11-12 /pmc/articles/PMC7690454/ /pubmed/33281620 http://dx.doi.org/10.3389/fphys.2020.590479 Text en Copyright © 2020 Checcoli, Pol, Naldi, Noel, Barillot, Kroemer, Thieffry, Calzone and Stoll. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Physiology
Checcoli, Andrea
Pol, Jonathan G.
Naldi, Aurelien
Noel, Vincent
Barillot, Emmanuel
Kroemer, Guido
Thieffry, Denis
Calzone, Laurence
Stoll, Gautier
Dynamical Boolean Modeling of Immunogenic Cell Death
title Dynamical Boolean Modeling of Immunogenic Cell Death
title_full Dynamical Boolean Modeling of Immunogenic Cell Death
title_fullStr Dynamical Boolean Modeling of Immunogenic Cell Death
title_full_unstemmed Dynamical Boolean Modeling of Immunogenic Cell Death
title_short Dynamical Boolean Modeling of Immunogenic Cell Death
title_sort dynamical boolean modeling of immunogenic cell death
topic Physiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7690454/
https://www.ncbi.nlm.nih.gov/pubmed/33281620
http://dx.doi.org/10.3389/fphys.2020.590479
work_keys_str_mv AT checcoliandrea dynamicalbooleanmodelingofimmunogeniccelldeath
AT poljonathang dynamicalbooleanmodelingofimmunogeniccelldeath
AT naldiaurelien dynamicalbooleanmodelingofimmunogeniccelldeath
AT noelvincent dynamicalbooleanmodelingofimmunogeniccelldeath
AT barillotemmanuel dynamicalbooleanmodelingofimmunogeniccelldeath
AT kroemerguido dynamicalbooleanmodelingofimmunogeniccelldeath
AT thieffrydenis dynamicalbooleanmodelingofimmunogeniccelldeath
AT calzonelaurence dynamicalbooleanmodelingofimmunogeniccelldeath
AT stollgautier dynamicalbooleanmodelingofimmunogeniccelldeath